Dr. Hristo Trunchev, country president at Novartis Bulgaria and president of the Association of Research-Based Pharmaceutical Manufacturers in Bulgaria (ARPharM), shares an overview of the business scenario for research-based pharmaceutical players in Bulgaria and explains the role of Novartis in bringing added-value medicines to the patients.
A lot has been happening with Novartis globally lately: with big changes to the product portfolio, plans underway to leverage cross-divisional synergies while generating efficiency gains of 1 billion USD per annum, and the recent FDA approval for Kymriah– the first genetic treatment to target Leukaemia. How are these developments affecting the Bulgarian business?
"We have a team of more than 250 professionals that ensure the success of Novartis in Bulgaria and a total turnover of around EUR 90 million."
